StockData
West Pharmaceutical Services Inc logo

West Pharmaceutical Services Inc (WST) stock

WSTNYSESurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 20/3031% above fair value
$412.62−4.05 (-0.97%)

Close on Oct 30, 2026Market cap $29.04BP/E 46.3Yield 0.21%

Earnings

West Pharmaceutical Services's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Feb 11, 2027
Q4 FY2026 · estimated, before the open
Revenue, Q3 FY2026
$874.50M
+8.7% on a year earlier
Adjusted-diluted EPS, Q3 FY2026
$2.66
$1.96 a year earlier
Latest guidance
Issued
Oct 29, 2026 · 5 items

Quarterly results

Revenue and earnings per share from each of West Pharmaceutical Services's earnings releases, newest first

QuarterReportedRevenueYoYEPSAdj. EPSSource
Q4 FY2026ended Dec 31, 2026Feb 11, 2027Expected–––––
Q3 FY2026ended Sep 30, 2026Oct 29, 2026before the open$874.50M+8.7%$3.02$2.66Release
Q2 FY2026ended Jun 30, 2026Jul 23, 2026before the open$872.30M+13.8%$2.15$2.37Release
Q1 FY2026ended Mar 31, 2026Apr 23, 2026before the open$844.90M+21.0%$1.92$2.13Release
Q4 FY2025ended Dec 31, 2025Feb 12, 2026before the open$805.00M+7.5%$1.82$2.04Release
Q3 FY2025ended Sep 30, 2025Oct 23, 2025before the open$804.60M+7.7%$1.92$1.96Release
Q2 FY2025ended Jun 30, 2025Jul 24, 2025before the open$766.50M+9.2%$1.82$1.84Release
Q1 FY2025ended Mar 31, 2025Apr 24, 2025before the open$698.00M+0.4%$1.23$1.45Release
Q4 FY2024ended Dec 31, 2024Feb 13, 2025before the open$748.80M+2.3%$1.78$1.82Release
Q3 FY2024ended Sep 30, 2024Oct 24, 2024before the open$746.90M-0.1%$1.85$1.85Release
Q2 FY2024ended Jun 30, 2024Jul 25, 2024before the open$702.10M-6.9%$1.51$1.52Release
Q1 FY2024ended Mar 31, 2024Apr 25, 2024before the open$695.40M-3.0%$1.55$1.56Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

West Pharmaceutical Services's latest outlook for periods it has not reported yet, compared with what it said before

MetricPeriodGuidanceBeforeChangeGiven
net salesGAAPFY2026$3.41B – $3.42B–NewOct 29, 2026
net salesGAAPFY2026$3.35B – $3.38B–NewJul 23, 2026
net salesFY2026$3.30B – $3.35B$3.22B – $3.28BRaisedApr 23, 2026
organic net sales growthnon-GAAPFY2026+10% – +11%+7% – +9%RaisedJul 23, 2026
Organic net sales growthnon-GAAPFY2026+11.3% – +11.6%–NewOct 29, 2026
Reported net sales growthGAAPFY2026+8.8% – +10%–NewJul 23, 2026
Reported net sales growthFY2026+7.2% – +9%+4.6% – +6.5%RaisedApr 23, 2026
Reported-diluted EPS (U.S. GAAP)GAAPFY2026$9.31 – $9.41–NewOct 29, 2026
Reported-diluted EPS (U.S. GAAP)GAAPFY2026$9.01 – $9.26$7.79 – $8.14RaisedJul 23, 2026
adjusted-diluted EPSnon-GAAPFY2026$9.38 – $9.48–NewOct 29, 2026
adjusted-diluted EPSnon-GAAPFY2026$8.85 – $9.05$8.40 – $8.75RaisedJul 23, 2026
capital spendingFY2026$215.00M – $220.00M–NewOct 29, 2026
Capital spendingFY2026$250.00M – $275.00M$250.00M – $275.00MReaffirmedJul 23, 2026

Guidance vs results

The last range West Pharmaceutical Services gave before each report, against the figure it then reported. Full years add up the four quarters.

PeriodMetricGuidanceActualResult
Q3 FY2026adjusted-diluted EPS$2.14 – $2.24$2.66Above range
Q3 FY2026Revenue$820.00M – $835.00M$874.50MAbove range
Q3 FY2026Revenue growth+1.9% – +3.8%+8.69%Above range
Q2 FY2026adjusted-diluted EPS$2.05 – $2.12$2.37Above range
Q2 FY2026Revenue$830.00M – $850.00M$872.30MAbove range
Q2 FY2026Revenue growth+8.3% – +10.9%+13.8%Above range
Q1 FY2026adjusted-diluted EPS$1.65 – $1.70$2.13Above range
Q1 FY2026Revenue$770.00M – $790.00M$844.90MAbove range
Q1 FY2026Revenue growth+10.3% – +13.2%+21.05%Above range
FY2025adjusted-diluted EPS guidance$7.06 – $7.11$7.29Σ4QAbove range
FY2025EPS (GAAP)$6.75 – $6.80$6.79Σ4QWithin range
FY2025Revenue$3.06B – $3.07B$3.07BΣ4QAbove range

Guidance history

Every forecast West Pharmaceutical Services put in an earnings release, newest first

GivenMetricPeriodGuidanceChange
Oct 29, 2026capital spendingFY2026$215.00M – $220.00MNew
Oct 29, 2026adjusted-diluted EPSFY2026$9.38 – $9.48New
Oct 29, 2026Reported-diluted EPS (U.S. GAAP)FY2026$9.31 – $9.41New
Oct 29, 2026Organic net sales growthFY2026+11.3% – +11.6%New
Oct 29, 2026net salesFY2026$3.41B – $3.42BNew
Jul 23, 2026Capital spendingFY2026$250.00M – $275.00MReaffirmed
Jul 23, 2026adjusted-diluted EPSFY2026$8.85 – $9.05Raised
Jul 23, 2026adjusted-diluted EPSQ3 FY2026$2.14 – $2.24New
Jul 23, 2026Reported-diluted EPS (U.S. GAAP)FY2026$9.01 – $9.26Raised
Jul 23, 2026Reported net sales growthFY2026+8.8% – +10%New
Jul 23, 2026organic net sales growthFY2026+10% – +11%Raised
Jul 23, 2026net salesFY2026$3.35B – $3.38BNew
Jul 23, 2026Reported net sales growthQ3 FY2026+1.9% – +3.8%New
Jul 23, 2026organic net sales growthQ3 FY2026+7% – +8.9%New
Jul 23, 2026net salesQ3 FY2026$820.00M – $835.00MNew
Apr 23, 2026Capital spendingFY2026$250.00M – $275.00MReaffirmed
Apr 23, 2026adjusted-diluted EPSFY2026$8.40 – $8.75Raised
Apr 23, 2026adjusted-diluted EPSQ2 FY2026$2.05 – $2.12New
Apr 23, 2026Reported net sales growthFY2026+7.2% – +9%Raised
Apr 23, 2026organic net sales growthFY2026+7% – +9%Raised

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.

Press releases

Releases West Pharmaceutical Services filed with the SEC as exhibits to Form 8-K or 6-K

  1. West Reports Third-Quarter 2026 Results
    Results
  2. West Pharmaceutical Services, Inc. Michel Lagarde President & CEO Bob McMahon Senior VP & Chief Financial Officer Third-Quarter 2026 Earnings Call October 29, 2026 | 8 a.m. Eastern Time
    Results
  3. West Reports Second-Quarter 2026 Results
    Results
  4. Quarterly results release
    Results
  5. 8-K exhibit EX-99.1
    Update
  6. 8-K exhibit EX-99.1
    Update
  7. West Reports First-Quarter 2026 Results
    Results
  8. Quarterly results release
    Results
  9. 8-K exhibit EX-99.1
    Update
  10. West Reports Fourth-Quarter and Full-Year 2025 Results
    Results
  11. Quarterly results release
    Results
  12. West Reports Third-Quarter 2025 Results
    Results
  13. Quarterly results release
    Results
  14. West Announces Second-Quarter 2025 Results and Fourth-Quarter 2025 Dividend, Updates Full-Year 2025 Guidance
    Results
  15. Quarterly results release
    Results